Safety and efficacy of GZR18, a long-acting GLP-1 analog, in Chinese patients with type 2 diabetes: A randomized, double-blind, phase 1b/2a trial
Ming Liu, Xuhong Wang, Meizi Li, Enyue Yang, Aige Yang, Mingxia Yuan, Ruihua Dong, Guijun Qin, Ping Liu, Chengqian Li, Yu Cao, Jing Zhao, Liyuan Zhao, Wei Chen · 2026
Read Safety and efficacy of GZR18, a long-acting GLP-1 analog, in Chinese patients with type 2 diabetes: A randomized, double-blind, phase 1b/2a trial by Ming Liu, Xuhong Wang, Meizi Li, Enyue Yang, Aige Yang, Mingxia Yuan, Ruihua Dong, Guijun Qin, Ping Liu, Chengqian Li, Yu Cao, Jing Zhao, Liyuan Zhao, Wei Chen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13400172.txt.
Description
Ming Liu and colleagues tested GZR18, also called bofanglutide, a once-weekly long-acting GLP-1 drug, in Chinese adults with type 2 diabetes, in a 2026 randomized double-blind phase 1b/2a trial. Seventy-two participants enrolled across two parts testing different titration ladders. Part A climbed from 0.5 to 4 milligrams over 26 weeks and Part B from 1.5 to 13 milligrams over 23 weeks, and sixty-two finished.
Blood sugar control improved decisively in both parts. Glycated hemoglobin fell by 1.32 percent on GZR18 against a rise of 0.86 percent on placebo in Part A, and by 1.81 percent against 0.12 percent in Part B. Tolerability matched the drug class: mostly mild-to-moderate gastrointestinal complaints, no severe hypoglycemia, and no treatment-related serious adverse events. The authors conclude the weekly injection is safe and effective enough to justify larger, longer trials.
Catalog record
| CREATOR | Ming Liu, Xuhong Wang, Meizi Li, Enyue Yang, Aige Yang, Mingxia Yuan, Ruihua Dong, Guijun Qin, Ping Liu, Chengqian Li, Yu Cao, Jing Zhao, Liyuan Zhao, Wei Chen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 52277 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |